INTRODUCTION
============

Acute respiratory illness (ARI) is a major cause of morbidity and mortality worldwide ([@B152]; [@B133]). ARI imposes a large burden on health, particularly in children. For community-based care, ARI has been estimated at a cost of over US\$100 per case ([@B28]). The disease burden for ARI is estimated at 94,037,000 disability-adjusted life years and 3.9 million deaths ([@B156]). Thus, ARI has a huge impact on health and society.

Although severe lower respiratory tract infections have been observed, ARI is most often associated with mild upper respiratory infection (URI). Most ARI cases in early childhood are confirmed as URI, leading to symptoms of the common cold with coryza and cough. In contrast, around one-third of infants with ARI develop lower respiratory tract symptoms such as tachypnea, wheezing, severe cough, breathlessness, and respiratory distress ([@B140]). In general, viruses are the most common causative agents of ARI. More than 200 different types of viruses are known to cause ARI, with respiratory syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus (HMPV), and human parainfluenza virus (HPIV) most commonly identified in ARI patients. Indeed, together with these respiratory viruses, human enterovirus (HEV), influenza virus (InfV), human coronavirus (HCoV), adenovirus (AdV), and human bocavirus (HBoV) account for around 70% of ARIs detected ([@B72]). Respiratory viral infections can have severe adverse outcomes in patients with established asthma and are associated with nearly 80% of asthma exacerbation episodes ([@B103]; [@B60]; [@B150]; [@B50]; [@B40]). Accumulating evidence indicates that the etiology of most cases of asthma, namely virus-induced asthma, is linked to such respiratory virus infections. In addition, RSV and HRV are the most frequently detected pathogens and may play an important role in viral induction and exacerbation of asthma.

Molecular biology techniques have developed rapidly over recent years. The application of molecular techniques to the study of virus-induced asthma enhances epidemiologic studies by improving our ability to classify these pathogens into meaningful groups ([@B32]). In this review, we focus on molecular epidemiological studies of respiratory viruses, including RSV, HRV, HMPV, and HPIV infections, associated with virus-induced asthma.

VIRAL INFECTION AND ASTHMA
==========================

In infancy, illnesses such as bronchiolitis share many clinical features with acute asthma, including wheezing, rapid breathing, prolonged expiratory phase inflammation, and respiratory compromise. Respiratory viruses are detected in the majority of asthma exacerbations in both children (80--85%) and adults (75--80%; [@B60]; [@B40]). In addition, wheezing illnesses are also closely associated with respiratory viral infections in all age groups ([@B35]). [@B33] attempted to detect various respiratory viruses in Japanese children with acute wheezing using PCR technology and found viruses in samples from 86.1% patients: RSV or HRV alone were detected in 40.9 and 31.3% patients, respectively and both RSV and HRV were detected in 12.2% patients. Other previous reports suggested that the prevalence of RSV and HRV is similar (36 and 42%, respectively) in children less than 2 years of age, but differs (27 and 66%) in older children ([@B60]; [@B40]). In addition, [@B33] suggested that RSV was the dominant species detected in patients with no history of wheezing and/or asthma, while HRV was dominant in patients with such a history. Thus, the main causative viral agent of asthma depends on previous illness and age.

Around one-third of infants who have an acute wheezing illness go on to develop recurrent wheezing, indicating that viral respiratory illnesses in early life promote asthma. Recently, the "two-hit" hypothesis has been proposed, whereby viral infections promote asthma mainly in predisposed children ([@B35]). Infants who develop virus-induced wheezing episodes are at increased risk for subsequent asthma, but most acute wheezing illnesses in infancy resolve with no long-term sequelae. It has been recognized for years that RSV infections often produce the first episode of wheezing in children who go on to develop chronic asthma ([@B80]). Indicators of heightened risk for developing asthma include wheezing episodes caused by HRV infections and the development of atopic features such as atopic dermatitis, allergen-specific IgE for foods or aeroallergens (e.g., house dust, mites, or cat or dog dander), and blood eosinophilia (**Figure [1](#F1){ref-type="fig"}**). Once asthma has been established, HRV infections are the most common cause of acute exacerbations, especially in children. As in infancy, atopy is an important risk factor for acute episodes of virus-induced wheezing ([@B73]). Many previous reports have suggested that such respiratory virus infections are deeply associated with virus-induced asthma ([@B73]; [@B114]; [@B71]; [@B33]; [@B65]). Thus, it is entirely plausible that viral infections induction and/or exacerbation asthma in children.

![**Relationship between respiratory viral infections and development of asthma.** Host-pathogen interactions that determine the severity of respiratory illnesses, and risk for subsequent asthma was increased by respiratory virus infection, especially due to RSV, in infants. Although most acute wheezing resolves within a relatively short time, a history of wheezing and host immunological conditions (e.g., atopic features) heightens the risk for asthma. Once asthma is established, HRV infections are the most common causative agents of asthma in children.](fmicb-04-00278-g001){#F1}

MOLECULAR EPIDEMIOLOGY OF RSV
=============================

Respiratory syncytial virus of genus *Pneumovirus* and family *Paramyxoviridae* causes ARI in children ([@B147]; [@B113]). RSV infection may cause major problems in infants less than 1 year of age and can lead to life-threatening ARIs such as bronchiolitis and bronchopneumonia ([@B126]; [@B81]; [@B160]). Epidemiological studies suggest that around 70% of infants have experienced an RSV infection by the age of 1 year, and 100% by the age of 2 years; host response to the virus varies greatly, but includes upper respiratory tract infections, typical bronchiolitis, and RSV-induced wheezy bronchitis ([@B18]; [@B71]). Long-term prospective case-control and cohort studies have also linked RSV bronchiolitis to the development of wheezing and asthma later in childhood ([@B128], [@B129], [@B127]; [@B46]). Thus, RSV infections may be associated with the initiation and/or exacerbation of asthma.

The RSV genome encodes 11 proteins ([@B113]). Among these, the attachment glycoprotein (G) is a major structural protein that may be associated with both infectivity and antigenicity ([@B59]; [@B120]). Molecular epidemiological studies have shown that RSV can be classified into two phylogenetic subgroups, RSV-A and RSV-B ([@B101]). The strains of subgroup A can be subclassified into eight genotypes (GA1--GA7 and SAA1), as can those of subgroup B (BA, GB1--GB4, and SAB1--3; [@B112]). From phylogenetic analysis of the *G* gene of RSV, [@B90] showed that RSV belonging to GA3 genotype may be associated with greater severity of illness in, for example, bronchiolitis and pneumonia. Although GA3 genotype has been detected in the United Kingdom, Spain, and New Zealand, it is not the most prevalent strain ([@B19]; [@B34]; [@B89]). [@B90] therefore suggested that the association between greater severity of illness and GA3 genotype may be solely due to a transient shift in genotype-specific immune status within the community. In addition, correlations between certain strains and/or genotypes of RSV and slight differences in disease severity have been described previously ([@B43]; [@B149]). Some genotypes such as subgroup A genotypes GA1, GA2, GA5, GA7, and NA1 and subgroup B genotype BA have been detected throughout the world in recent years ([@B163]; [@B112]; [@B162]; [@B102]; [@B116]). Of these, NA1 is a novel genotype known to be genetically close to GA2 genotype, while GA2 genotype and BA genotype are the most common genotypes of RSV subgroups A and B around the world and have persisted for many years ([@B139]). Furthermore, a new genotype belonging to RSV-A, ON1, has been detected in some countries, including Canada, Korea, Malaysia, South Africa, and Japan ([@B29]; [@B79]; [@B67]; [@B141]; [@B143]). This genotype contains a unique tandem repeat (72nt sequence duplication) in the C-terminal 3rd hypervariable region of the *G* gene, and may be classified as a subdivision of NA1 ([@B29]). Some reports have suggested that the severity of illness is not linked to subgroups or genotypes, but is associated with the quantity of RSV in nasopharyngeal aspirate ([@B134]; [@B17]). A larger population study is needed to identify the different RSV genotypes circulating in different areas to gain a better understanding of the relationship between disease severity and RSV genotype.

The G protein is a major antigen of RSV and amino acid substitutions may be related to changes in antigenicity. There are some reports of amino acid substitutions, and some positively selected sites in the C-terminal 3rd hypervariable region of the *G* gene have been estimated ([@B12]; [@B161]; [@B74]). For example, [@B161] estimated some sites under positive selection in the region (Asn250Ser, Met262Glu, Arg297Lys,and Arg297Glu substitutions in RSV-A strains were estimated by the REL method, and Asn273Tyr and Leu274Pro substitutions of RSV-A, as well as Leu237Pro substitution of RSV-B, were estimated by the IFEL method). [@B12] found 29 and 23 amino acid sites under putative positive selection in RSV-A and RSV-B, respectively. In addition, some unique positively selected sites were found in the *G* gene ([@B74]). These amino acid variations at these sites might play a key role in severe respiratory infection, such as bronchiolitis ([@B38]). Furthermore, the rate of molecular evolution of the region might be high. For example, [@B74] estimated the evolutionary rate of RSV-A at 3.63 × 10^-3^ substitutions/site/year, while that of RSV-B was estimated at 4.56 × 10^-3^ substitutions/site/year. Thus, it is suggested that this C-terminal 3rd hypervariable region in the *G*gene of RSV-A and -B evolved rapidly ([@B74]). Based on host immunological conditions, it is suggested that host immunity such as TLR4 polymorphism is linked to symptomatic RSV infection ([@B26]). Thus, both the antigenicity of the viruses and host immune conditions may play important roles in the pathophysiology of severe respiratory infections such as bronchiolitis, pneumonia, and virus-induced asthma ([@B7]).

MOLECULAR EPIDEMIOLOGY OF HRV
=============================

Human rhinovirus are a group of positive-sense ssRNA viruses belonging to genus *Enterovirus* in the family *Picornaviridae* ([@B142]). Although HRVs were previously thought to be mainly associated with the common cold causing mild respiratory symptoms, recent reports strongly suggest that HRVs may induce and/or exacerbate asthma (virus-induced asthma; [@B20]; [@B142]; [@B15]; [@B35]; [@B66]). One report suggested that HRV wheezing illness within the first three years of life is significantly associated with the development of asthma at age 6 years ([@B56]). Another report suggested that HRVs are major agents in the induction of wheezing and exacerbation of asthma ([@B66]). Thus, HRVs are being re-evaluated as important agents of ARI in humans ([@B53]; [@B108]; [@B157]). The basis for these lower respiratory symptoms has been a source of controversy in terms of the mechanisms of HRV pathogenesis. There are a variety of potential barriers to HRV infection of the lungs, including temperature-sensitive replication of the virus. For this reason, it is thought that the optimum propagation temperature of HRVs may be 32--35°C *in vitro* ([@B107]; [@B124]). However, a recent study suggested that HRVs can propagate in lower airway tissues and this may be an important factor in the development of airway obstruction, coughing, and wheezing that can lead to bronchiolitis and pneumonia ([@B100]). HRV has been concomitantly isolated with bacterial pathogens in 24--54% of children and 10--18% of adults with pneumonia ([@B61]; [@B136]; [@B58]). Thus, it is not clear whether HRV is ever the causative agent for the disease.

Human rhinovirus were previously classified into two species, HRV species A (HRV-A) and species B (HRV-B), containing over 100 serotypes ([@B142]). However, a genetically heterogeneous third species, HRV species C (HRV-C), was discovered recently ([@B76]; [@B92]). Recent reports suggest that HRV-A, B, and C have a unique and wide genetic diversity ([@B93]; [@B130]; [@B5]). HRV-A and -C appear to be mainly associated with ARIs and virus-induced asthma, while HRV-B has been detected in a relatively small number of patients with ARIs ([@B82]; [@B154]; [@B132]). Our previous findings obtained from samples from children with ARIs in Japan indicated that HRV-A and -C can be classified into many clusters in the phylogenetic tree, with 30% nucleotide divergence of the *VP4/VP2* coding region ([@B95]; [@B5]; [@B68]). In addition, [@B68] estimated that the rate of molecular evolution of the *VP4/VP2*coding region was rapid (3.07 × 10^-3^ substitutions/site/year) in HRV-C. These results suggest that HRV-A and -C detected in ARI cases are the predominant strains and have varied genetic properties ([@B154]; [@B95]; [@B5]). Thus, the association between HRV type and disease severity is not fully understood. There may be important differences in the susceptibility of individuals to the replication of HRV in lower airway tissues.

[@B111] and [@B36] found that weak peripheral blood mononuclear cell (PBMC) Th1 (IFN-γ) response to HRV infection is associated with increased viral shedding, and decreased proliferative response of PBMCs to HRV is associated with increased severity of symptoms. In addition, it was found that weak Th1 responses (IFN-γ/IL-5 mRNA ratio) in sputum are also associated with greater severity of illness ([@B36]). Furthermore, weak Th1 responses to viral infection in adults with asthma have been associated with decreased lung function and greater airway responsiveness ([@B13]). These results indicate that individuals with a weak Th1 response to viruses, and perhaps individuals with asthma in general, may be more susceptible to HRV illnesses, and this association may be strongest in those with more severe disease ([@B111]; [@B36]; [@B13]). Other epidemiological and biological factors, such as allergy, atopic dermatitis, or a family history of allergy, may be related to virus-induced asthma ([@B39]; [@B131]). Recently it is suggested that variants at the 17q21 locus were associated with HRV induced asthma in children who had a history wheezing illnesses, although associations of 17q21 variants with asthma were restricted to children who had a history of HRV wheezing illnesses (Calişkan et al., 2013).

MOLECULAR EPIDEMIOLOGY OF HMPV
==============================

Human metapneumovirus is a recently identified RNA virus belonging to the *Paramyxoviridae* family, of genus *Metapneumovirus* ([@B21]). HMPV is a major pathogen that causes ARI in all ages ([@B21]). The first HMPV infection appears to take place within the first six months of life, after which infections may occur repeatedly and frequently ([@B123]). The nosocomial impact of HMPV is estimated to be as high as that for RSV. In an HMPV outbreak in Japan, 34.8% of elderly patients who shared the same day care room in a hospital were infected with HMPV ([@B51]). Higher morbidity is observed in young children, the elderly, and immunocompromised adults ([@B11]; [@B31]; [@B145]; [@B135]; [@B153]; [@B104]). HMPV is classified into two genotypes (A and B) and four subgroups (A1, A2, B1, and B2) by phylogenetic analysis, using the *F* and *G* genes ([@B9]; [@B144]). Subgroup A2 has been subdivided into two lineages, subgroup A2a and A2b ([@B52]). It has been suggested that these genotypes circulate in variable proportions in some areas ([@B37]; [@B86]). Although the molecular epidemiological information on HMPV has gradually accumulated, the detailed epidemiology remains unclear ([@B96]; [@B115]; [@B105]). HMPV infections can occur throughout the year, but seasonality has been described in several studies, with the epidemiological peak occurring several months later than that observed for RSV epidemics ([@B119]; [@B151]; [@B87]; [@B3], [@B2]; [@B45]). It remains unclear whether different HMPV subgroups are associated with differences in the clinical course of disease. Several groups have suggested that HMPV subgroup A might be associated with more severe clinical disease ([@B90]; [@B62]; [@B148]; [@B6]), while others have reported that subgroup B may cause more severe illness ([@B30]; [@B115]), and still other groups have found no evidence for differential severity caused by different HMPV lineages ([@B4]; [@B88]; [@B77]; [@B158]). Previous reports suggested that the substitution rates for the *G* gene (3.5 × 10^-3^ substitution/site/year) and the *F* gene (7.1 × 10^-4^ to 8.5 × 10^-4^ substitution/site/year) are high, and some positively selected sites have been found in the latter ([@B25]; [@B159]). It may be that there is a correlation between some positively selected epitopes and disease severity. Thus, the association between HMPV subgroup and disease severity is controversial. To gain a better understanding of host responses that may contribute to differences in clinical severity between HMPV subgroups, a more detailed analysis that includes host immunological status is needed.

MOLECULAR EPIDEMIOLOGY OF HPIV
==============================

Human parainfluenza virus belong to the *Paramyxoviridae* family. There are two genera of HPIV, *Respirovirus* (HPIV-1 and HPIV-3) and *Rubulavirus* (HPIV-2 and HPIV-4; [@B64]). HPIV is classified into four serotypes (HPIV1--4), all of which can cause various ARI in humans such as URI, croup, bronchitis, asthma, and pneumonia ([@B47]; [@B64]). Although HPIV type 4 (HPIV4) is rarely reported, HPIV1-3 are important causes of various ARI, including the common cold, croup, bronchitis, bronchiolitis, and pneumonia in children, and they commonly re-infect both children and adults. While such infections are generally mild in healthy persons, they may cause serious diseases in children, such as asthma ([@B47]; [@B64]). Although fewer HPIV strains have been detected compared with other respiratory viruses such as RSV, HRV, and HMPV, previous reports suggest that HPIV1 and 3 are the dominant viruses in children with ARI ([@B117]). Indeed, serological surveys indicate that at least 60% of children have been infected with HPIV3 by 2 years of age, approximately 80% have been infected by age 4, and at least 75% have been infected with HPIV1 by 5 years of age ([@B110], [@B109]). HPIV1 and 3 show high prevalence and are associated with up to 12% of acute lower respiratory tract infections in adults ([@B8]; [@B91]). HPIV1 and HPIV3, may be major agents of ARI throughout the world, along with other viruses such as RSV, HRV, and HMPV ([@B78]; [@B55]; [@B99]; [@B27]). In addition, it is suggested that HPIV is a major causative agent of virus-induced asthma ([@B49]). Several previous studies have reported that HPIV1 infections demonstrate clear outbreaks in autumn, mostly in September and November, every 2 years ([@B70]; [@B41]; [@B22]). Other studies have reported that HPIV3 causes yearly outbreaks around the globe, mainly in the spring-summer season ([@B70]; [@B22]; [@B41]; [@B97]). A recent study suggested that four different types of HPIV cause similar clinical manifestations in patients, and the clinical presentation of HPIV infection may differ depending on patient age ([@B84]).

[@B48] analyzed the longitudinal evolution of the HN coding region in 13 strains of HPIV1 isolated in the USA. These results showed that the antigenic and genetic subgroups are very stable. In addition, [@B98] suggested that the evolution of the *HN* gene in the present HPIV1 isolates was relatively slow and that the gene is highly conserved. Only a few reports on the molecular epidemiology of HPIV1 are available and it appears that the molecular epidemiology of HPIV is poorly understood. Larger and more detailed studies on the association of HPIV with asthma are needed.

MOLECULAR EPIDEMIOLOGY OF OTHER VIRUSES
=======================================

HEV68 was recently detected in asthmatic patients ([@B44]). HEV68 was found to be relatively acid resistant and thus could be distinguished from acid-sensitive HRV87 ([@B122]; [@B63]). HRV87 was recently reclassified as HEV68 based on phylogenetic analysis and neutralization test, and some laboratories have confirmed its acid sensitivity ([@B10]; [@B54]; [@B121]). Distinguishing between HRV and HEV based on the acid sensitivity of isolates is therefore not appropriate for HEV68. The number of reports of an association between respiratory disease and HEV68 infection has recently increased. One report of the phylogenetic analysis of HEV68 based on partial VP1 gene sequences indicates wide genetic diversity ([@B83]). In addition, [@B137] showed the presence of multiple clades among the circulating strains, and that all strains are spreading rapidly worldwide and contributing to the prevalence rates of respiratory diseases. In addition, asthmatic individuals infected with HEV68 also have the propensity to develop unstable asthma or an acute attack ([@B44]).

Influenza virus is also a major causative agent of ARI in both children and adults. Furthermore, asthmatic patients were found among children and adults hospitalized with seasonal InfV ([@B23]; [@B24]). Although it is recognized that viral infections such as RSV or HRV may induce and/or exacerbate asthma, the effect of InfV on asthma remains arguable ([@B60]). Although one study suggested that A(H1N1)pdm09 viruses impose greater risk factors on children than seasonal InfV ([@B138]), InfV vaccine was available before the influenza season since InfV causes more severe illness than other respiratory viruses. Therefore, it is suggested that InfV vaccine be recommended for children with asthma ([@B69]).

Although the level of detection of HCoV, HBoV, or AdV is relatively low, these infections are also detected in children with acute wheezing ([@B20]; [@B57]). Further studies are needed to clarify the clinical roles of HCoV, HBoV, or AdV infections and those of other respiratory viruses. In particular, the prevalence of HCoV, HBoV, or AdV infection in healthy control subjects, assessment of disease severity by other clinical variables, and the immunological effects should be investigated.

MOLECULAR EPIDEMIOLOGY OF CO-INFECTION
======================================

Infants with severe bronchiolitis have an increased risk of developing recurrent wheezing later in life ([@B20]). HRV may be detected concurrently with other viruses such as RSV, HMPV, InfV, or HCoV ([@B118]; [@B33]). Considering their ubiquity, it is interesting that the number of respiratory viruses detected concurrently with HRV strains is relatively low ([@B75]; [@B85]), supporting the concept that HRVs have a direct role in the clinical outcome of infection ([@B94]). In fact, HRV strains are co-detected with other pathogens in reproducible, but clinically undefined, patterns ([@B14]). The HRV partnership with host immunity may be a mutualistic one, inadvertently imparting an advantage to the host by protecting against more cytopathic respiratory viral pathogens while the host provides a vessel for HRV replication and transmission.

Respiratory viruses other than RSV and multiple viral infections may contribute to the severity of bronchiolitis and asthma. Indeed, it was reported that dual infections of HMPV and RSV or HRV and RSV confer a 5- to 10-fold increase of severe disease in children admitted to pediatric intensive care units ([@B108]; [@B125]). In contrast, other studies reported that co-infection with two respiratory viruses was not significantly associated with disease severity ([@B146]; [@B155]). Thus, there is no consensus on the effects of co-infection on disease severity. The effect of dual infection may depend upon which viruses co-infect together. For example, although there was no increase in severity when HRV and/or AdV were detected during RSV infection, co-infection with both HMPV and RSV increased the rate of intensive care unit admissions ([@B1]; [@B125]). Thus, although dual infections and reinfections have been well documented in children, chronic infection with the development of quasispecies cannot be ruled out without obtaining more complete data using high performance detection methods ([@B42]).

CONCLUSION
==========

Respiratory viral infections are a major cause of virus-induced asthma in early life. Although antiviral therapy is not yet available for patients infected with respiratory viruses, the detection and identification of these viruses could help to explain serious respiratory illness, provide guidance for medical care, and prevent unnecessary treatment with antibiotics. Based on the results of many related studies, we propose a two-step hypothesis of asthma development in children. The first step is mainly due to RSV infection: when RSV infects bronchial cells, the bronchial cells produce various cytokines and chemokines. These responses cause hyperresponsiveness in the bronchial cells. In other words, RSV infection might create a preparatory step as the first step in the development of asthma. HRV infection might then bring about the second step in the development of asthma. An infant with a history of wheezing caused by RSV infection may develop the heavy wheezing of asthma due to HRV infection followed by RSV infection. To understand the cause of asthma, we need to examine the larger complex picture of genetic susceptibility, immune components, environmental exposures, and the interactions between these elements.
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